ViiV Healthcare announces positive Week 48 results in first study to evaluate treatment switch from TAF-containing regimen with three or more drugs to 2-drug regimen of dolutegravir/lamivudine for HIV-1 infection - Argus Press

ViiV Healthcare announces positive Week 48 results in first study to evaluate treatment switch from TAF-containing regimen with three or more drugs to 2-drug regimen of dolutegravir/lamivudine for HIV-1 infection  Argus Press

LONDON--(BUSINESS WIRE)--Jul 24, 2019--. Today ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi ...



Comments

Popular posts from this blog

Is Citronella Safe for Dogs? A Veterinarian Provides Guidance

Everything You Need to Know About Mite and Flea Bites

The Best Flea Treatments for Cats and Dogs